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This study aimed to characterize the role of Pseudomonas aeruginosa low-molecular-mass penicillin-binding proteins (LMM
PBPs), namely, PBP4 (DacB), PBP5 (DacC), and PBP7 (PbpG), in peptidoglycan composition, -lactam resistance, and ampC
regulation. For this purpose, we constructed all single andmultiple mutants of dacB, dacC, pbpG, and ampC from the wild-type
P. aeruginosa PAO1 strain. Peptidoglycan composition was determined by high-performance liquid chromatography (HPLC),
ampC expression by reverse transcription-PCR (RT-PCR), PBP patterns by a Bocillin FL-binding test, and antimicrobial suscep-
tibility byMIC testing for a panel of-lactams. Microscopy and growth rate analyses revealed no apparent major morphological
changes for any of the mutants compared to the wild-type PAO1 strain. Of the single mutants, only dacCmutation led to signifi-
cantly increased pentapeptide levels, showing that PBP5 is the major DD-carboxypeptidase in P. aeruginosa. Moreover, our re-
sults indicate that PBP4 and PBP7 play a significant role as DD-carboxypeptidase only if PBP5 is absent, and their DD-endopepti-
dase activity is also inferred. As expected, the inactivation of PBP4 led to a significant increase in ampC expression (around 50-
fold), but, remarkably, the sequential inactivation of the three LMMPBPs produced a much greater increase (1,000-fold), which
correlated with peptidoglycan pentapeptide levels. Finally, the -lactam susceptibility profiles of the LMMPBPmutants corre-
lated well with the ampC expression data. However, the inactivation of ampC in these mutants also evidenced a role of LMM
PBPs, especially PBP5, in intrinsic -lactam resistance. In summary, in addition to assessing the effect of P. aeruginosa LMM
PBPs on peptidoglycan structure for the first time, we obtained results that represent a step forward in understanding the impact
of these PBPs on-lactam resistance, apparently driven by the interplay between their roles in AmpC induction, -lactam trap-
ping, and DD-carboxypeptidase/-lactamase activity.
Pseudomonas aeruginosa is a frequent cause of nosocomial in-fections, especially affecting patients in intensive care units
(ICUs) with mechanical ventilation-associated pneumonia or
burn wound infections, both of which are associated with a high
mortality rate (1). This pathogen is also themajor cause of chronic
respiratory infections in patients with cystic fibrosis and other
underlying chronic respiratory diseases (2). One of themost strik-
ing features of P. aeruginosa is its extraordinary capacity for devel-
oping resistance to almost any available antibiotic by the selection
of mutations in chromosomal genes (3). Among the mutation-
mediated -lactam resistance mechanisms, particularly notewor-
thy are those leading to the constitutive overexpression of the
inducible chromosomal cephalosporinase AmpC, which confers
resistance to penicillins, cephalosporins, and monobactams (4).
Additionally, mutations that lead to the repression or inactivation
of the porin OprD, acting synergistically with inducible or consti-
tutively overexpressed AmpC, confer resistance to carbapenems
(5, 6).
AmpC is a group I class C -lactamase that hydrolyzes effi-
ciently penicillins and cephalosporins but not carbapenems. An
AmpC-produced phenotype can be plasmidic or chromosomal.
In P. aeruginosa, ampC is chromosomally carried and can be in-
duced by certain -lactams, such as cefoxitin and carbapenems,
which are designated AmpC inducers (7, 8). AmpC expression is
tightly linked to peptidoglycan recycling and involves multiple
enzymes, including the AmpG permease, AmpD amidase ho-
mologs (AmpD, AmpDh2, and AmpDh3), NagZ, and the LysR
superfamily transcriptional regulator AmpR. Additionally, two
competing AmpR-binding muropeptides, the UDP-MurNAc-
pentapeptides (AmpC repressors) and the 1,6-anhydromuropep-
tides (AmpC inducers), play a major role in the regulation of
AmpC expression (9, 10). In the absence of -lactams, GlcNAc-
N-acetylmuramic acid (MurNAc)–1,6-anhydromuropeptides are
shed from the peptidoglycan and find their way via AmpG per-
mease to the cytoplasm. In the cytoplasm, they are processed by
the -N-acetylglucosaminidase NagZ to generate MurNAc–1,6-
anhydromuropeptides (11). These peptides replace the repressor
UDP-MurNAc-pentapeptides from the AmpR-binding site,
which in turn undergoes a conformational change that leads to
AmpC induction (12). On the other hand, AmpD eliminates pep-
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tide stems (tri-, tetra-, and pentapeptides) from anhydromuro-
peptides. This reaction results in the repression of ampC expres-
sion, because it cleaves the inducer anhydromuropeptides and
generates the peptidoglycan recycling components needed for the
synthesis of the repressor UDP-MurNAc-pentapeptides. How-
ever, during exposure to AmpC-inducing -lactams, MurNAc–
1,6-anhydromuropeptides accumulate in the cytoplasm, leading
to AmpC induction (13, 14).
The classical mechanisms of ampC overexpression include the
mutational inactivation of AmpD or specific mutations in the
ampR-ampC intergenic region or in AmpR itself (4, 15). More
recently, mutations of the nonessential dacB gene encoding the
DD-carboxypeptidase PBP4 were found to frequently determine
AmpC overexpression and high-level -lactam resistance in vitro
and among P. aeruginosa clinical strains (16). Interestingly, mu-
tations of P. aeruginosa PBP4 were also shown to lead to the acti-
vation of the CreBC-BlrAB two-component regulator that also
plays a significant role in -lactam resistance. Moreover, BlrAB
is the regulator of several -lactamases in Aeromonas spp., and
recent studies suggest that the disruption of DacB triggers activa-
tion of the system through the elevation of the monomer-disac-
charide-pentapeptide levels (17). Further recent studies show that
several other P. aeruginosa enzymes involved in cell wall metabo-
lism, including UDP-N-acetylmuramate:L-alanyl--D-glutamyl-
meso-diaminopimelate ligase (Mpl), NADH dehydrogenase I
chain N (NuoN), and several lytic transglycosylases (SltB1 and
MltB), may also have an effect on ampC expression (18, 19). In-
deed, the targeting of -lactamase expression pathways, particu-
larly through the inhibition of NagZ or AmpG, has been proposed
as a useful approach to combat -lactam resistance in P. aerugi-
nosa and other AmpC-producing Gram-negative rods (6, 20–22).
Penicillin-binding proteins (PBPs) are a group of periplasmic
enzymes responsible for polymerization, cross-linking, and mod-
ification of the bacterial peptidoglycan (23, 24). Peptidoglycan is
the sacculus envelope outside the cytoplasmic membrane. It
maintains cell shape and strength against intracellular pressure
(23, 25). According to their molecular structure, PBPs are classi-
fied into high-molecular-mass (HMM) and low-molecular-mass
(LMM) PBPs (3). All of them have a penicillin-binding domain.
HMM PBPs were further classified into class A (e.g., PBP1) and
class B (e.g., PBP2 and PBP3). They are responsible for pepti-
doglycan polymerization, cross-linking, and insertion of the pep-
tidoglycan precursors into the preexisting strands through trans-
glycosylation and transpeptidation reactions (3). LMMPBPswere
grouped as class C PBPs and subdivided into 4 subgroups (types 4,
5, 7 and AmpH) with reference to Escherichia coli (3). Type 4 class
C PBPs (e.g., PBP4) have endopeptidase and carboxypeptidase
activity. Type 5 class CPBPs (e.g., PBP5) are themain DD-carboxy-
peptidases. Type 7 class C PBPs (e.g., PBP7) are DD-endopepti-
dases. Type AmpH class C PBPs (e.g., AmpH) have been charac-
terized in E. coli as bifunctional DD-carboxypeptidase and
DD-endopeptidase enzymes with a structure similar to that of class
C -lactamases (3). PBP5 is the most abundant LMM PBP of E.
coli, and it has an important role in the control of cell diameter and
correct septum formation (3). Recent studies suggest that E. coli
LMM PBPs, particularly PBP5, play a role in intrinsic -lactam
resistance (26, 27). Moreover, the recently crystalized P. aerugi-
nosa PBP5 shows certain -lactamase activities, adding further
interest to the role of LMM PBPs in antibiotic resistance (28).
In the light of all these findings, the objective of the present
work was to systematically investigate the potential roles of the
main P. aeruginosa LMM PBPs (DacB, PBP4; DacC, PBP5; and
PbpG, PBP7) in peptidoglycan structure,-lactam resistance, and
AmpC regulation. For this purpose, all possible combinations of
single and multiple LMM PBPs and AmpC mutants were gener-
ated and analyzed.
MATERIALS AND METHODS
Construction of P. aeruginosa strain PAO1 knockout mutants. The
strains and plasmids used and constructed in this study are listed in Table
S1 in the supplemental material. The conditions for knockout construc-
tions were adapted from those described by Moya et al. (16) based on the
cre-lox system for gene deletion and antibiotic resistancemarker recycling
in P. aeruginosa (29). Previously constructed plasmids (pEXTampC::
Gm and pEXTdacB::Gm) were used for the generation of dacB and
ampCmutants (16, 30). For the construction of plasmids for dacCor pbpG
inactivation, the PCR products (using PAO1 DNA as the template) of the
upstream and downstream sequences (see Table S2 in the supplemental
material) were digested with either BamHI or EcoRI and HindIII and
cloned by three-way ligation into pEX100Tlink with the HindIII site de-
leted and opened by EcoRI and BamHI. The resulting plasmids
(pEXTdacC and pEXTpbpG) were transformed into the E. coli XL1-
Blue strain. Transformants were selected in 30 g/ml ampicillin LB agar
plates. The lox-flanked gentamicin resistance cassette (aac1) obtained by
HindIII restriction of plasmid pUCGmlox was cloned into the single site
for this enzyme, formed by the ligation of the two flanking fragments. The
resulting plasmids (pEXTdacC::Gm and pEXTpbpG::Gm) were again
transformed into E. coli XL1-Blue. Transformants were selected in 30
g/ml ampicillin-5 g/ml gentamicin LB agar plates. The plasmids were
then transformed into the E. coli S17-1 helper strain. Knockout mutants
were generated by conjugation, followed by the selection of double re-
combinants using 5% sucrose-1 g/ml cefotaxime-30 g/ml gentamicin
LB agar plates. Double recombinants were checked by first screening for
carbenicillin (200g/ml) susceptibility and afterwards by PCR amplifica-
tion and sequencing. For the recycling of the gentamicin resistance cas-
settes, plasmid pCM157 was electroporated into the different mutants.
Transformants were selected in LB agar plates with 250 g/ml tetracy-
cline. One transformant for each mutant was grown overnight in 250
g/ml tetracycline LB broth to allow the expression of the cre recombi-
nase. Plasmid pCM157 was then cured from the strains by successive
passages in LB broth. Selected colonies were then screened for their tetra-
cycline (250 g/ml) and gentamicin (30 g/ml) susceptibilities and
checked by PCR amplification and DNA sequencing. Double, triple, and
quadruple mutants were then generated sequentially, using the same pro-
cedure.
ampC expression. The expression of the gene encoding P. aeruginosa
AmpC (ampC) was determined by real-time reverse transcription-PCR
(RT-PCR) for the constructed mutants and PAO1 (as a control), accord-
ing to previously described protocols (31). For the quantification of ampC
induction, the strains were incubated in the presence of 50 g/ml cefoxi-
tin. Briefly, total RNA from logarithmic-phase-grown LB cultures was
obtainedwith an RNeasyminikit (Qiagen, Hilden, Germany). Fifty nano-
grams of purified RNA was then used for one-step reverse transcription
and real-time PCR using a QuantiTect SYBR green reverse transcription-
PCR kit (Qiagen) in an Eco real-time PCR system (Illumina, Inc.). Previ-
ously described conditions and primers were used (31). The rpsL house-
keeping gene was used to normalize the expression levels, and the results
were always referenced against PAO1 basal expression. All RT-PCRs were
performed in duplicate, and the mean values of mRNA expression result-
ing from three independent experiments were considered in all cases.
Antimicrobial susceptibility testing.TheMICs of ampicillin, pipera-
cillin, aztreonam, cefotaxime, ceftazidime, cefepime, cefoxitin, imi-
penem, meropenem, and vancomycin were determined by microdilution
in 100 l of cation-adjusted Mueller-Hinton broth, according to Clinical
and Laboratory Standards Institute (CLSI) guidelines (32). Vancomycin
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permeates the outer membranes of Gram-negative bacteria very slowly
because of its large size, which demonstrates that these microorganisms
show intrinsic clinical resistance to this antibiotic. However, vancomycin
can still kill Gram-negative bacteria at a clinically unobtainable concen-
tration through the samemechanism by which it kills Gram-positive bac-
teria: binding to the terminal D-alanine–D-alanine of muropentapeptides
in peptidoglycan. Thus, vancomycin MICs can be used as markers of the
peptidoglycan pentapeptide levels (17).
Preparation of peptidoglycan and analysis of muropeptides. Well-
established previously described procedures were used for peptidoglycan
preparation (33, 34). The wild type and the differentmutants of P. aerugi-
nosa PAO1 were cultured in LB medium treated with and without 50
g/ml cefoxitin (FOX) at 37°C and 180 rpm agitation until an optical
density at 600 nm (OD600) of 0.75 to 0.8 was achieved. The cells were
then collected by centrifugation at 5,000 rpm and 4°C and resuspended in
1 phosphate-buffered saline (PBS) buffer (pH 7.5). One fraction from
this cell suspension was left at 20°C for membrane preparation (see
below). The rest of cell suspension was added drop by drop to an equal
volume of boiling 6%SDS solutionwith strong stirring. The final cell-SDS
suspension was left under boiling conditions for 12 h with stirring. The
cell-SDS suspensions were centrifuged at 60,000 rpm for 10min to collect
the sacculi from the pellet fraction, which was then washed with warm
sterile Milli-Q water at least three times. Peptidoglycan was suspended in
10 ml of 10 mM Tris-HCl (pH 7.2) and digested with 100 g/ml 	-amy-
lase (Sigma-Aldrich, St. Louis, MO) for 1 h at 37°C and then with 100
g/ml preactivated pronase E (Merck, Darmstadt, Germany) at 60°C for
90 min. The enzymes were inactivated by boiling for 20 min in 1% (final
concentration) SDS. Next, peptidoglycan was collected and washed as
described above. After that, peptidoglycan was digested with 100 g/ml
Cellosylmuramidase (Hoechst AG, Frankfurt, Germany) in 50mMphos-
phate buffer (pH 4.9) at 37°C overnight. Next, the enzymewas inactivated
by boiling the sample for 10min in a water bath and centrifuged at 14,000
rpm for 5 min to remove insoluble debris. The supernatant was mixed
with 1/3 volume of 0.5M sodiumborate buffer (pH 9.0) and reducedwith
excess sodium borohydride (NaBH4) for 30 min at room temperature.
The pHwas testedwith pH indicator strips (Acilit;Merck) and adjusted to
pH 3 with orthophosphoric acid. All samples were filtered (Millex-GV
filters, 0.22-m pore size, 2.5-mm diameter; Millipore, Cork, Ireland)
and injected into the HPLC. Separations were performed on a Breeze 2
HPLC system, consisting of a 1525 binary HPLC pump model code 5CH
(Waters), a UV-visible detector 2489 (Waters), a manual injector model
7725i (Rheodyne), and an Aeris Peptide XB-C18, 3.6 m, 250 by 4.6 mm
reverse-phase column (Phenomenex). Separation of individual compo-
nents (muropeptides) of peptidoglycan was performed in a linear gradi-
ent, the columnwas equilibrated at 45°C, and the eluted compounds were
detected at a wavelength of 204 nm. The mobile-phase (A 
 50 mM
sodium phosphate [pH 4.35]; B
 75mM sodium phosphate, 15%meth-
anol [pH 4.95]) gradient consisted of elution at 1.0 ml/min with 100% A
for 5min, followed by a 60-min linear gradient to 0%A/100% B and then
100% B for 5 min.
The identification of individual muropeptides was carried out accord-
ing to retention time, using a comparison analysis with the retention times
of known muropeptides. When a difference was found in the retention
time of a particular peak, this peak was purified, and the structure was
confirmed or characterized by matrix-assisted laser desorption ioniza-
tion–time of flight (MALDI-TOF) mass spectrometry with the autoflex
spectrometer (Bruker Daltonics). Finally, the relative abundances of mu-
ropeptides present in each sample were determined by integrating their
respective areas of absorption (Breeze 2, Waters program) and expressed
as the molar fraction (mol%) relative to the total content. The average
values from three biological replicates, showing in all cases a variation of
5%, are shown.
Cellmembrane preparation for Bocillin FL-binding test.The frozen
fractions of cell suspension (during peptidoglycan preparation) of the
different PAO1 mutants were thawed, sonicated, and centrifuged at
265,000 g for 40min using the TL-100 ultracentrifuge at 4°C. The pellet
was resuspended in 1 PBS (pH 7.5) and used for the Bocillin FL-binding
test. In order to avoid possible Bocillin FL degradation by the presence of
AmpC in the membrane fractions, an alternative protocol that included
several washing steps was also performed. Briefly, 500-ml late-log-phase
(OD600, 1) LB cultures were collected by centrifugation and then washed
and suspended in 50 ml of 20 mMKH2PO4-140 mMNaCl (pH 7.5). The
cells were then sonicated and centrifuged at 12,000 g for 10 min. Mem-
branes containing the PBPs were isolated from the supernatant through
one step of ultracentrifugation at 150,000 g and 4°C for 1 h, followed by
two washing steps, using an Optima L-XP series preparative ultracentri-
fuge (Beckman Coulter, Inc., Palo Alto, CA).
Bocillin FL-binding test. Previously described procedures (33) were
used for the Bocillin FL-binding test, with some modifications. Briefly,
100 g of membrane proteins was incubated with 10 M Bocillin FL
(Invitrogen, Carlsbad, CA) in 1 PBS (pH 7.5) at 37°C for 30 min. Next,
a proper volume of loading sample buffer was added. The samples were
left at 100°C for 10 min, centrifuged using an Eppendorf centrifuge at
maximum speed for 5 min, and loaded to 8% acrylamide gels in an SDS-
PAGE system and run at 90 V. After the run, the gels were left in fixing
solution (10%methanol and 7% acetic acid) for 1 to 2 h and then visual-
ized on a Typhoon 9410 variable-mode imager (General Electric) at 588
nm, with a 520 BP 40 emission filter. For the determination of cefoxitin
50% inhibitory concentrations (IC50) for the different PBPs, 100 g of
membrane proteins was incubated first with serial concentrations from 0
to 1,500g/ml cefoxitin at 37°C for 30min, and then they were incubated
with 20 M Bocillin FL at 37°C for 30 min and processed as described
above. The IC50 was calculated as the cefoxitin concentration producing a
50% reduction in Bocillin FL binding for each individual PBP.
Cell preparation formicroscopic examination.Overnight cultures of
PAO1 wild-type and mutant strains were used to inoculate fresh LB me-
dium and left to grow at 37°C and 180 rpm for about 8 h. The optical
density at 600 nmwasmeasured every 1 h with a U-2000 spectrophotom-
eter (Hitachi). Also, at different time intervals, the cell morphology was
tested in vivo using fluorescence resonance energy transfer (FRET) equip-
ment comprising an Axiovert 200 invertedmicroscope (Zeiss) coupled to
a monochrome CCD camera.
RESULTS
Constructionof single andcombinedmutants in the threeLMM
PBPs and AmpC of P. aeruginosa. In order to evaluate the role of
the three P. aeruginosa LMM PBPs (DacB [PBP4], DacC [PBP5],
and PbpG [PBP7]) and AmpC in -lactam resistance, ampC ex-
pression, and peptidoglycan structure, the four single, six double,
four triple, and two quadruple mutants were generated using the
cre-lox system, as described in Materials and Methods. The PAO
dacB and PAO ampC single mutants were available from pre-
vious studies (16), while the PAO pbpG and PAO dacC mu-
tants were constructed from wild-type PAO1 in this work. The
PAO dacB dacC, PAO dacB pbpG, and PAO dacB ampC
double mutants were generated from PAO dacB, while PAO
dacC ampC and PAO pbpG ampC were constructed from
PAOampC, and PAOdacCpbpGwas constructed from PAO
pbpG. The PAO dacC pbpG ampC triple mutant was con-
structed fromPAOdacCpbpG and PAOdacBdacCampC
from PAO dacB dacC; both PAO dacB dacC pbpG and
PAO dacB pbpG ampC were generated from PAO dacB
pbpG. Finally, the quadruple mutants were constructed in two
ways, with PAO dacB pbpG ampC dacC constructed from
PAO dacB pbpG ampC and PAO dacB dacC pbpG
ampC constructed from PAOdacBdacCpbpG. Although it
was not a primary objective of this work, microscopy and growth
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rate analyses revealed no apparent major changes compared to
wild-type PAO1, even for the quadruple mutants (not shown).
The Bocillin FL-binding patterns of PBPs (1a, 1b, 2, 3, 4
[DacB], 5 [DacC], and 7 [PbpG]) were checked through SDS-
PAGE ofmembrane extracts from the differentmutants (Fig. 1A).
The observed patterns correlated well with the loss of the expected
PBP for each mutant. However, as revealed in Fig. 1A, the band
corresponding to DacC was almost absent in the PAO dacB and
PAO dacB pbpG mutants. On the other hand, the DacC band
was present in the PAO dacB ampC and PAO dacB pbpG
ampCmutants. Therefore, these results suggested that the large
amounts of AmpC produced by DacBmutants (see below) signif-
icantly compromised the Bocillin FL concentration required for
DacC visualization. To confirm this hypothesis, the cell mem-
brane preparation protocol was modified to include additional
washing steps to avoid the contamination of the membrane frac-
tions with AmpC. Indeed, as shown in Fig. 1B, the expression of
DacC was not modified in the dacB, pbpG, or ampC mutants.
Moreover, DNA sequencing and gene expression analysis (RT-
PCR) revealed no modification of dacC in these mutants (not
shown).
Role of P. aeruginosa LMM PBPs in ampC expression. The
basal and cefoxitin-induced ampC expression levels for all the
single and combined LMM PBPmutants of PAO1 are shown in
Table 1. In agreement with previous data (16), the inactivation
of DacB caused a marked (47-fold) increase in basal ampC
expression. On the other hand, the inactivation of DacC or
PbpG did not cause a significant modification of either basal or
induced ampC expression levels. Likewise, the DacB-PbpG
double mutant did not show modified ampC expression com-
pared to that of the DacB mutant. In contrast, the inactivation
of DacC in the DacB mutant caused a further major increase in
basal ampC expression (478-fold compared to PAO1 and 10-
fold compared to the DacB single mutant). Moreover, the basal
and induced ampC expression levels were highest in the DacB-
DacC-PbpG triple mutant, reaching levels 1,000-fold higher
than those of PAO1.
Role of P. aeruginosa LMM PBPs in -lactam resistance. In
agreement with previous data (16), the inactivation of DacB
caused a marked increase in the MICs for the antipseudomonal
penicillins (piperacillin), cephalosporins (cefotaxime, ceftazi-
dime, and cefepime), and monobactams (aztreonam), which was
consistent with the documented AmpC hyperproduction. As was
also expected, the MICs of strong AmpC-inducing -lactams, in-
cluding the carbapenems (imipenem andmeropenem), cefoxitin,
and ampicillin, were barely modified. On the other hand, the in-
activation of DacC or PbpG did not cause a significant modifica-
tion of the MIC for any -lactam, with the exception of a slight
decrease in piperacillin susceptibility in the DacC mutant. Con-
sistent with the ampC expression data, the MICs for antipseudo-
monal penicillins, cephalosporins, and monobactams were fur-
ther increased in the DacB-DacC double mutant. Of all -lactams
tested, the highest MIC increase, compared to the DacB single
mutant, was documented for piperacillin. On the other hand, un-
like for ampC expression, -lactam resistance was not further in-
creased in the DacB-DacC-PbpG triple mutant (Table 1).
To determine the direct effect of the inactivation of the LMM
PBPs on -lactam resistance, susceptibility testing was also per-
formed with all combinations of LMM PBPs and AmpC mutants
(Table 1). As expected, the inactivation of AmpC in wild-type
PAO1 produced a marked increase in the susceptibility of strong
AmpC-inducing -lactams, including the carbapenems, cefoxi-
tin, and ampicillin, whereas the MICs of weak AmpC-inducing
-lactams (antipseudomonal penicillins, cephalosporins, and
monobactams) were not significantly modified. Interestingly, the
MICs for nearly all -lactams were lower in the DacC-AmpCmu-
tant than those in the AmpC single mutant, and this effect was
further enhanced in the DacB-DacC-PbpG-AmpC mutant, indi-
cating that LMM PBPs, particularly DacC, play a role in the in-
trinsic level of -lactam resistance in P. aeruginosa.
FIG 1 Bocillin FL binding test of PAO1 wild-type and derived mutants. (A) Conventional cell membrane preparation protocol. (B) Modified protocol to avoid
AmpC contamination of cell membrane preparations leading to Bocillin FL hydrolysis. The PBP pattern (at left) of all the constructed P. aeruginosamutants and
the wild-type PAO1 (lanes 1 to 18) were visualized by fluorescence scanning using the Typhoon 9410 variable-mode imager at 588 nm, with a 520 BP 40 emission
filter, after an SDS-PAGE run of the reaction samples in 8% acrylamide gels, in which each reaction involved an incubation of 100 g of cell membrane protein
with 10 M Bocillin FL at 37°C for 30 min. Lanes 1 and 10, wild-type PAO1; lane 2, PAO dacB; lane 3, PAO dacC; lane 4, PAO pbpG; lane 5, PAO dacB
dacC; lane 6, PAOdacBpbpG; lane 7, PAOdacCpbpG; lane 8, PAOdacBdacCpbpG; lane 9, PAOampC; lane 11, PAOdacBampC; lane 12, PAO
dacCampC; lane 13, PAOpbpGampC; lane 14, PAOdacBdacCampC; lane 15, PAOdacBpbpGampC; lane 16, PAOdacCpbpGampC; lane
17, PAO dacB pbpG ampC dacC; and lane 18, PAO dacB dacC pbpG ampC.
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Role of P. aeruginosa LMMPBPs in peptidoglycan composi-
tion. The composition of the peptidoglycan of all PAO1 mutants
was studied through muropeptide HPLC analysis, and the results
are shown in Table 2; representative chromatograms of pepti-
doglycan muropeptides of the constructed mutants are also
shown in Fig. 2 and Table S3 in the supplemental material. No
major differences in DAP-DAP cross-linked and lipoprotein-
bindingmuropeptides, both of them due to LD-transpeptidase ac-
tivity, were found. Also, no major changes in peptidoglycan com-
position were observed for any of three LMMPBP singlemutants,
with the exception of a significant increase (4.4-fold) in the pen-
tapeptide levels in the DacC mutant. Therefore, these results sug-
gest that DacC is the primary DD-carboxypeptidase of P. aerugi-
nosa. Moreover, pentapeptide levels were significantly increased
(17.9-fold) in the DacB-DacC double mutant and still further en-
hanced (41.5-fold) in the DacB-DacC-PbpG triple mutant. Thus,
TABLE 1 MICs and ampC expression under basal and cefoxitin induction conditions for all studied mutants
Strain or mutant
MIC (g/ml) fora: ampC expressionb
AMP PIP ATM CTX CAZ CEF FOX IMI MER VAN Basal Induced
PAO1 1,024 2 4 12 1 1 1,024 0.5 0.5 512 347 59
PAO ampC 32 2 4 8 1 1 64 0.12 0.25 512
PAO dacB 1,024 16 8 256 8 4 1,024 1 0.5 512 47 29 569 166
PAO dacB ampC 32 2 2 8 1 0.5 96 0.12 0.25 512
PAO dacC 1,536 4 2 8 0.75 0.5 1,024 0.5 0.5 1,024 1.3 0.4 542 380
PAO dacC ampC 16 2 2 4 0.75 0.5 64 0.06 0.25 1,024
PAO pbpG 512 4 4 16 1 1 1,024 1 0.5 512 0.6 0.3 305 152
PAO pbpG ampC 32 4 3 8 1 0.5 96 0.12 0.25 512
PAO dacB dacC 1,024 128 16 512 16 4 1,024 0.5 0.5 2,048 478 5.1 840 245
PAO dacB dacC ampC 16 2 2 4 1 0.5 64 0.06 0.12 4,096
PAO dacB pbpG 2,048 16 8 256 8 4 1,024 0.5 0.25 512 45 32 326 106
PAO dacB pbpG ampC 32 2 2 6 0.75 0.5 64 0.12 0.5 4,096
PAO dacC pbpG 1,024 6 2 8 1 0.5 1,024 0.5 0.25 1,024 1.4 0.7 162 87
PAO dacC pbpG ampC 24 3 2 4 0.75 0.5 64 0.06 0.25 1,024
PAO dacB dacC pbpG 1,024 128 16 512 16 4 1,024 0.5 0.5 4,096 1,207 193 5,742 1,975
PAO dacB pbpG ampC dacC 16 2 2 4 0.5 0.5 64 0.06 0.12 4,096
PAO dacB pbpG dacC ampC 16 2 1 4 0.5 0.5 64 0.06 0.12 4,096
a AMP, ampicillin; PIP, piperacillin; ATM, aztreonam; CTX, cefotaxime; CAZ, ceftazidime; CEF, cefepime; FOX, cefoxitin; IMI, imipenem; MER, meropenem; VAN, vancomycin.
The median values from 3 experiments are shown.
b Relative ampC expression (with respect to wild-type PAO1) without induction (basal) and after induction with 50 g/ml cefoxitin (induced). The mean values from three
independent experiments standard deviation are shown.
TABLE 2 HPLC analysis of muropeptides prepared from the peptidoglycan of the different mutants
Strain or mutant
Relative abundance (mol%) of muropeptidea:
Cross-linkb D-D/Tc
Peptidoglycan
lengthdMono Di Tri D-D Lpp Anh Penta
PAO1 57.8 38.3 3.9 1.9 3.1 8.7 1.6 46.1 4.1 11.5
PAO dacB 56.1 (1.0) 39 (1.0) 4.8 (1.2) 1.5 (0.8) 3.7 (1.2) 9.6 (1.1) 2.4 (1.5) 48.9 (1.1) 3.1 (0.8) 10.5 (0.9)
PAO dacC 59.3 (1.0) 37.1 (1.0) 3.6 (0.9) 1.1 (0.6) 3.2 (1.0) 9.1 (1.1) 7.1 (4.4) 44.4 (1.0) 2.4 (0.6) 11 (1.0)
PAO pbpG 58.7 (1.0) 37.2 (1.0) 4.1 (1.1) 1.5 (0.8) 2.8 (0.9) 9.4 (1.1) 1.4 (1.0) 45.4 (1.0) 3.2 (0.8) 10.7 (0.9)
PAO dacB dacC 58.4 (1.0) 36.7 (1.0) 4.8 (1.2) 1.1 (0.6) 3.4 (1.1) 9.4 (1.1) 28.6 (17.9) 46.6 (1.0) 2.3 (0.6) 10.7 (0.9)
PAO dacB pbpG 54.5 (0.9) 39.5 (1.0) 5.9 (1.5) 1.5 (0.8) 3.3 (1.1) 14.2 (1.6) 2.5 (1.6) 51.6 (1.1) 2.9 (0.7) 7 (0.6)
PAO dacC pbpG 55.9 (1.0) 39.4 (1.0) 4.6 (1.2) 1.2 (0.6) 3.3 (1.1) 8.9 (1.0) 9.8 (6.1) 48.8 (1.1) 2.6 (0.6) 11.2 (1.0)
PAO dacB dacC pbpG 54.7 (1.0) 40 (1.0) 5.2 (1.3) 1.3 (0.7) 2.4 (0.8) 7.6 (0.9) 66.4 (41.5) 50.6 (1.1) 2.5 (0.6) 13.2 (1.2)
PAO ampC 59.9 (0.9) 36.3 (1.0) 3.8 (1.0) 1.2 (0.6) 3.3 (1.1) 9 (1.0) 2.5 (1.6) 43.8 (1.0) 2.8 (0.7) 11.1 (1.0)
PAO dacB ampC 54.2 (1.0) 40.3 (1.0) 5.4 (1.4) 2.1 (1.1) 4.1 (1.3) 10.3 (1.2) 2.5 (1.6) 51.2 (1.1) 4.1 (1.0) 9.8 (0.9)
PAO dacC ampC 59.7 (1.0) 36.6 (1.0) 3.7 (1.0) 1.1 (0.6) 3.2 (1.0) 9.1 (1.0) 8 (5.0) 44.1 (1.0) 2.4 (0.6) 11 (1.0)
PAO pbpG ampC 56.4 (1.0) 38.6 (1.0) 4.9 (1.3) 1.5 (0.8) 3.7 (1.2) 9.7 (1.1) 2.5 (1.6) 48.5 (1.1) 3.1 (0.8) 10.3 (0.9)
PAO dacB dacC ampC 59.4 (1.0) 36.1 (0.9) 4.4 (1.1) 1 (0.5) 2.5 (0.8) 7.9 (0.9) 32 (20.0) 45.2 (1.0) 2 (0.5) 12.6 (1.0)
PAO dacB pbpG ampC 49.4 (0.9) 43.5 (1.1) 7 (1.8) 1.7 (0.9) 3.6 (1.2) 11.3 (1.3) 3.7 (2.3) 57.8 (1.3) 3 (0.7) 8.8 (0.8)
PAO dacC pbpG ampC 54.9 (1.0) 39.9 (1.0) 5.1 (1.3) 1.8 (1.0) 3.7 (119) 9.4 (1.1) 9.4 (5.9) 50.4 (1.1) 3.5 (0.9) 10.7 (0.9)
PAO dacB dacC pbpG ampC 54.8 (1.0) 40 (1.0) 5.1 (1.3) 0.6 (0.3) 2.1 (68) 7.2 (0.8) 67.6 (42.2) 50.4 (1.1) 1.1 (0.3) 13.9 (1.2)
PAO dacB pbpG ampC dacC 53 (0.9) 40.4 (1.1) 6.5 (1.7) 1.5 (0.8) 2.4 (77) 8.8 (1.0) 65.9 (41.2) 53.6 (1.2) 2.8 (0.7) 11.4 (1.0)
a Mono, monomers; Di, dimers; Tri, trimers; D-D, muropeptides having Dap-Dap peptide bridges; Lpp, muropeptides bound to C-terminal Arg-Lys dipeptide of Braun’s
lipoprotein; Anh, muropeptides having anhydro-1,6-anhydromuramic acid; Penta, muropeptides having a pentapeptide stem. Values in parentheses represent the ratio of the
values obtained for each mutant and wild-type PAO1.
b Cross-link, degree of peptidoglycan cross-linking (percentage). Values in parentheses represent the ratio of the values obtained for each mutant and wild-type PAO1.
c D-D/T, percent ratio of Dap-Dap cross-links to total peptidoglycan cross-links. Values in parentheses represent the ratio of the values obtained for each mutant and wild-type
PAO1.
d Values in parentheses represent the ratio of the values obtained for each mutant and wild-type PAO1.
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these results indicate that DacB plays a significant role as a DD-
carboxypeptidase when DacC is absent, and the DD-carboxypep-
tidase activity of PbpG is apparent only when both DacC and
DacB are inactivated. Moreover, as expected, the pentapeptide
levels correlated well with the MICs of vancomycin (Table 1), a
glycopeptide that specifically binds to the D-Ala-D-Ala residues of
pentapeptides.
Additionally, the peptidoglycan of theDacB-PbpGdoublemu-
tant had more anhydromuropeptides and slightly higher cross-
linking than those of the wild-type PAO1; these data should indi-
cate the inhibition of DD-endopeptidase activity; this strongly
suggests that both DacB and PbpG should also have this function
and that they can complement each other (since only marginal
effects are evidenced in the single mutants). No significant differ-
ences were found in the structure of the peptidoglycan of these
mutants compared with those containing the ampC deletion (Ta-
ble 2).
Effect of cefoxitin on peptidoglycan composition. The effect
of the exposure to the AmpC inducer cefoxitin on the composi-
tion of the peptidoglycan of all PAO1mutants is shown in Table 3.
Since cefoxitin induces AmpC expression and the -lactamase
efficiently degrades this antibiotic, information from the collec-
tion of AmpCmutants is of primary interest here (i.e., the absence
of AmpC significantly enhances the effect of cefoxitin). Exposure
to cefoxitin in the AmpC mutant (and, to a lower extent, also in
wild-type PAO1) significantly increased pentapeptide levels (from
2.5 mol% to 14mol%) but also resulted in fewer monomers (59.9
mol% versus 54.9 mol%), more dimers (36.3 mol% versus 40.3
mol%), and higher cross-linking (43.8% versus 50%). Therefore,
these results strongly suggest that exposure to cefoxitin inhibits
the DD-carboxypeptidase and DD-endopeptidase activities of
LMM PBPs to some degree. To confirm and quantify the potency
of such inhibition, cefoxitin IC50s were determined, and the re-
sults are shown in Table 4. As can be observed, of all the P. aerugi-
nosa PBPs, the highest affinity (in the range of 1 to 2 g/ml) was
documented for DacB and PbpG. Although still 10 g/ml, the
affinity for DacC was significantly lower. As can be observed in
Table 3, these results are consistent with the information obtained
from the analysis of the peptidoglycan composition of the LMMPBP
mutants exposed tocefoxitin. For instance,pentapeptide levelsnearly
reached themaximum values (60mol%) in the DacC-AmpCmu-
tant, indicating that the DD-carboxypeptidase activity of DacB and
PbpG is fully abolished upon cefoxitin exposure. On the other hand,
the only significant change observed in the DacB mutant when ex-
posed to cefoxitin is an increase in the anhydromuropeptide levels
FIG 2 High-performance liquid chromatograms of peptidoglycan muropeptides of the wild-type and constructed PAO1 mutants. Each series displays peaks
corresponding to the common muropeptides in peptidoglycan of the given PAO1 strain (indicated at right). Each peak corresponds to a muropeptide whose
name (in bold) and retention time (RT) (in minutes) are indicated at the top. M3, disaccharide tripeptide; M4G, disaccharide tetrapeptide with Gly at position
4; M4, disaccharide tetrapeptide; M5, disaccharide pentapeptide in which L-Ala, D-Glu, Dap (meso-diaminopimelic acid), D-Ala, and D-Ala occupy positions 1,
2, 3, 4, and 5, respectively, and L-Ala is linked to N-acetylmuramic acid; M5G, disaccharide pentapeptide with Gly at position 5; D44, cross-linked dimer of
disaccharide tetrapeptide-disaccharide tetrapeptide; D43, cross-linked dimer of disaccharide tetrapeptide-disaccharide tripeptide; D45, cross-linked dimer of
disaccharide tetrapeptide-disaccharide pentapeptide; T444, cross-linked trimer of disaccharide tetrapeptide-disaccharide tetrapeptide-disaccharide tetrapep-
tide; T445, cross-linked trimer of disaccharide tetrapeptide-disaccharide tetrapeptide-disaccharide pentapeptide; anhydro-muropeptides D44N, D45N, T444N,
and T445N have the same structures as muropeptides D44, D45, T444, and T445, respectively, but with anhydro-N-acetylmuramic acid instead ofN-acetylmu-
ramic acid. Each disaccharide is composed of N-acetylglucosamine and N-acetylmuramic acid.
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(from 9.6 mol% to 13.7 mol%), similar to what is observed for the
DacB-PbpG double mutant in the absence of cefoxitin.
DISCUSSION
Role of P. aeruginosa LMM PBPs in cell wall physiology. Previ-
ous analyses of the P. aeruginosa cell membrane identified eight
proteins able to bind [3H]benzylpenicillin or 125I-ampicillin,
(PBP1a, PBP1b, PBP2, PBP3, PBP3b, PBP4, PBP5, and PBP7)
(35–37), and in silico analysis, using the Pseudomonas Genome
Database (38), revealed the presence of eight open reading frames
annotated as encoding potential penicillin-binding proteins. In
this study, we used a fluorescence-labeled antibiotic (Bocillin FL)
to identify PBPs of wild-type and mutant strains of PAO1. The
PBP patterns of single- and multiple-deletion mutants correlated
well with the loss of the expected PBP for each mutant (PBP4
[DacB], PBP5 [DacC], and PBP7 [PbpG]). These PBPs belong to
the class C LMM PBP types 4, 5, and 7, respectively. All PBPs in
these subclasses have DD-endopeptidase and/or DD-carboxypepti-
dase activity. The largest changes in peptidoglycan structure (in-
crease in pentapeptide content) were observed for the DacB-
DacC-PbpG triple mutant, with a structure similar to the nine-
PBP deletionmutant of E. coli, in which all DD-endopeptidase and
DD-carboxypeptidase activities were depleted, causing aberrant
cellular morphology in E. coli (39). Therefore, these three PBPs
must represent the major endolytic machinery of P. aeruginosa.
The crystal structure of P. aeruginosa PBP5 (DacC) reveals a pro-
tein fold that is highly similar to the related E. coli PBP5 and PBP6
and alsomore closely resemble features seen previously only in the
class A -lactamases (28). Gram-negative bacteria most often
have a major type 5 PBP, which is the most abundant PBP they
produce (24). The most highly expressed PBP in P. aeruginosa
membranes has been documented to be PBP5 (40), consistent
with the results of our work. It was recently shown that PBP5 is a
DD-carboxypeptidase that preferentially degrades low-molecular-
weight substrates (28). In this work, we confirm that PBP5 is the
major DD-carboxypeptidase in P. aeruginosa, as evidenced by the
fact that of the three LMMPBP single mutants, only dacCmutation
led to significantly increased pentapeptide levels. Moreover, our re-
sults indicate that DacB plays a significant role as DD-carboxypepti-
dase onlywhenDacC is absent, and the DD-carboxypeptidase activity
of PbpG is apparent only when bothDacC andDacB are inactivated.
On the other hand, the peptidoglycan structure of dacB and pbpG
single and double mutants indicated that P. aeruginosa PBP4 and
PBP7 have DD-endopeptidase activity, as previously suggested for E.
coli (41). Moreover, our results are consistent with very recent data
demonstrating that purified P. aeruginosa PBP4 shows both DD-car-
boxypeptidase and DD-endopeptidase activities (42).
TABLE 3 HPLC analysis of muropeptides prepared from the peptidoglycan of the different PAO1 mutants with FOX treatment
Strain or mutant
Relative abundance (mol%) of muropeptidea:
Cross-linkb D-D/Tc
Peptidoglycan
lengthdMono Di Tri D-D Lpp Anh Penta
PAO1 55.5 (1.0) 39.3 (1.0) 5.1 (1.3) 1.9 (1.0) 3.7 (1.2) 10.1 (1.2) 4.4 (2.8) 49.9 (1.1) 3.7 (0.9) 9.9 (0.9)
PAO dacB 57.1 (1.0) 37.2 (1.0) 5.6 (1.2) 1.7 (1.1) 3.4 (0.9) 13.7 (1.4) 3.7 (1.5) 48.6 (1.0) 3.5 (1.1) 7.3 (0.7)
PAO dacC 55.2 (0.9) 39.6 (1.1) 5.1 (1.4) 1.2 (1.1) 2.5 (0.8) 8.2 (0.9) 38.8 (5.5) 50.1 (1.1) 2.3 (1.0) 12.3 (1.1)
PAO pbpG 56.6 (1.0) 37.9 (1.0) 5.4 (1.3) 1.9 (1.3) 3.6 (1.3) 8.9 (1.0) 4.2 (3.0) 49.0 (1.1) 3.9 (1.2) 11.3 (1.1)
PAO dacB dacC 58.8 (1.0) 36.7 (1.0) 4.4 (0.9) 1.1 (1.0) 3.2 (0.9) 8.1 (0.9) 39.8 (1.4) 45.8 (1.0) 2.4 (1.0) 12.4 (1.2)
PAO dacB pbpG 51.0 (0.9) 42.1 (1.1) 6.8 (1.2) 2.1 (1.4) 4.9 (1.5) 12.3 (0.9) 4.0 (1.6) 56.1 (1.1) 3.7 (1.3) 8.2 (1.2)
PAO dacC pbpG 54.3 (1.0) 40.3 (1.0) 5.3 (1.2) 1.0 (0.8) 2.6 (0.8) 7.5 (0.8) 44.0 (4.5) 51.3 (1.1) 1.8 (0.7) 13.4 (1.2)
PAO dacB dacC pbpG 54.8 (1.0) 39.0 (1.0) 6.0 (1.2) 1.1 (0.9) 3.1 (1.3) 9.3 (1.2) 66.0 (1.0) 51.6 (1.0) 2.1 (0.8) 10.8 (0.8)
PAO ampC 54.9 (1.0) 40.3 (1.1) 4.6 (1.2) 1.3 (1.1) 2.6 (0.8) 7.2 (0.8) 14.0 (5.6) 50.0 (1.1) 2.6 (0.9) 14.0 (1.3)
PAO dacB ampC 55.8 (1.0) 39.5 (1.0) 4.5 (0.8) 1.3 (0.6) 3.4 (0.8) 7.7 (0.8) 16.5 (6.6) 48.9 (1.0) 2.7 (0.7) 13.1 (1.3)
PAO dacC ampC 58.1 (1.0) 37.0 (1.0) 4.8 (1.3) 1.4 (1.3) 3.4 (1.1) 7.5 (0.8) 62.3 (7.8) 46.9 (1.1) 3.0 (1.3) 13.3 (1.2)
PAO pbpG ampC 53.9 (1.0) 40.6 (1.1) 5.4 (1.1) 1.8 (1.2) 3.1 (0.8) 8.2 (0.9) 14.1 (5.6) 51.7 (1.1) 3.5 (1.2) 12.3 (1.2)
PAO dacB dacC ampC 56.9 (1.0) 37.6 (1.0) 5.3 (1.2) 1.2 (1.2) 2.6 (1.0) 7.5 (1.0) 63.1 (2.0) 48.8 (1.1) 2.5 (1.3) 13.3 (1.1)
PAO dacB pbpG ampC 53.4 (1.1) 40.6 (0.9) 5.8 (0.8) 1.9 (1.1) 3.6 (1.0) 8.3 (0.7) 14.7 (4.0) 52.8 (0.9) 3.6 (1.2) 12.0 (1.4)
PAO dacC pbpG ampC 55.8 (1.0) 38.5 (1.0) 5.5 (1.1) 1.3 (0.7) 2.8 (0.8) 7.3 (0.8) 64.6 (6.9) 50.2 (1.0) 2.5 (0.7) 13.7 (1.3)
PAO dacB dacC pbpG ampC 57.0 (1.0) 37.2 (0.9) 5.6 (1.1) 1.3 (2.2) 2.7 (1.3) 6.7 (0.9) 63.1 (0.9) 49.1 (1.0) 2.7 (2.3) 15.0 (1.1)
PAO dacB pbpG ampC dacC 57.2 (1.1) 36.7 (0.9) 5.9 (0.9) 1.0 (0.7) 2.0 (0.8) 7.4 (0.8) 65.5 (1.0) 49.0 (0.9) 1.9 (0.7) 13.5 (1.2)
a Mono, monomers; Di, dimers; Tri, trimers; D-D, muropeptides having Dap-Dap peptide bridges; Lpp, muropeptides bound to C-terminal Arg-Lys dipeptide of Braun’s
lipoprotein; Anh, muropeptides having anhydro-1,6-anhydromuramic acid; Penta, muropeptides having a pentapeptide stem.
b Cross-link, degree of peptidoglycan cross-linking (percentage). Values in parentheses represent the ratio of the values obtained for each strain with and without cefoxitin
exposure.
c D-D/T, percent ratio of Dap-Dap cross-links to total peptidoglycan cross-links. Values in parentheses represent the ratio of the values obtained for each strain with and without
cefoxitin exposure.
d Values in parentheses represent the ratio of the values obtained for each strain with and without cefoxitin exposure.
TABLE 4 Estimated IC50s of cefoxitin for PAO1 and PAO ampC PBPs using Bocillin FL test
Strain or mutant
IC50 of FOX (g/ml) for
a:
PBP1a PBP1b PBP2 PBP3 PBP4 (DacB) PBP5 (DacC) PBP7 (PbpG)
PAO1 6.4 30.7 16.4 8 1.5 9.1 1.5
PAO ampC 4.8 27.2 15.4 7.7 1.3 6.5 1.5
a Cefoxitin (FOX) concentration producing a 50% reduction in Bocillin FL binding for each individual PBP.
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Nomajor effect on cell morphology or growth parameters was
seen for any of the single, double, or triple mutants, suggesting
that themajor changes observed in the peptidoglycan structure do
not affect significantly the morphology of the cell under labora-
tory conditions. In E. coli, it was reported that PBP5 inactivation
was the only single mutation of LMM PBPs to produce an aber-
rant cellular shape; however, the further inactivation of PBP6 or
PBP4 and PBP7 caused more deformation in cell morphology
(43–45). In parallel with our findings within P. aeruginosa, it was
found in E. coli that multiple mutants of all possible LMM PBPs
did not affect their growth curves in LB medium at 37°C, and the
cells were viable (39, 46). However, the in vivo role, and particu-
larly the impact on virulence, of P. aeruginosa LMM PBPs still
needs to be explored.
P. aeruginosa LMM PBPs and AmpC induction. It is well
known that exposure to certain-lactams, such as cefoxitin or the
carbapenems, leads to the induction ofAmpCexpression. Current
models consider that the specific effects on the cell wall produced
by subinhibitory concentrations of these drugs determine the ac-
cumulation of MurNAc-1,6-anhydromuropeptides in the cyto-
plasm, which replace UDP-MurNAc-pentapeptides from AmpR,
leading to AmpC induction (9). Early studies found a correlation
between the AmpC-inducing potency of -lactams and their af-
finity for certainE. coliLMMPBPs, in particular PBP4 (47).More-
over, years later, we demonstrated that the inactivation of dacB,
which encodes PBP4, is amajormechanism of AmpC overexpres-
sion in P. aeruginosa (16). These data suggested a major role of
LMM PBPs in AmpC induction; however, the specific effects on
the cell wall triggering the AmpC induction response are mostly
unknown. A recent work using Aeromonas hydrophila as a model
organism showed that PBP4 inactivation also led to -lactamase
overexpression, and this correlated with a 2-fold increase in pep-
tidoglycan pentapeptide levels, presumably caused by reduced DD-
carboxypeptidase activity (17). Our P. aeruginosa results show,
however, that PBP5 is the major DD-carboxypeptidase, and the
PBP5 mutant is the only LMM PBP single mutant producing a
significant increase in pentapeptide levels (up to 4.4-fold higher
than those of wild-type PAO1). Thus, increased peptidoglycan
pentapeptide levels, or apparently any other effect on peptidogly-
can structure (Table 2), does not explain, at least for P. aeruginosa,
the major role of PBP4 in AmpC induction. Whether the PBP4
effect is driven by significantly increasing periplasmic soluble an-
hydromuropeptides levels leading to the activation of classical
AmpC induction pathway needs still to be explored. This possi-
bility is indeed supported by the fact that the phenotype requires a
functional AmpG (6) and AmpR (16), and by very recent PBP4
catalytic data (42). In any case, our results suggest that increased
peptidoglycan pentapeptide levels explain the major role of PBP5
in ampC expression when PBP4 is absent. Indeed, except for the
specific effect of PBP4, a correlation between peptidoglycan pen-
tapeptide levels and ampC expression was documented.
P. aeruginosa LMM PBPs and -lactam resistance. As could
be anticipated, the MICs for the antipseudomonal penicillins (pip-
eracillin), cephalosporins (cefotaxime, ceftazidime, and cefepime),
and monobactams (aztreonam) correlated well with the ampC ex-
pression data (Table 1); theywere significantly increased in theDacB
mutant and further increased in the DacB-DacC doublemutant. On
the other hand, unlike for ampC expression,-lactam resistance was
not further increased in theDacB-DacC-PbpG triplemutant. Besides
theobviouseffectonresistancedrivenby the impactonampCexpres-
sion, we askedwhetherP. aeruginosa LMMPBPs had a direct effect
on -lactam susceptibility. For this purpose, we analyzed the
-lactam MICs for all combinations of LMM PBPs and AmpC
mutants. As expected (5, 6), the inactivation ofAmpC inwild-type
PAO1 produced a marked increase in the susceptibility of strong
AmpC-inducing -lactams, including the carbapenems, cefoxi-
tin, and ampicillin, whereas the MICs of weak AmpC-inducing
-lactams (antipseudomonal penicillins, cephalosporins, and
monobactams) were not significantly modified. Remarkably, the
MICs of nearly all -lactams were lower for the DacC-AmpCmu-
tant than those for the AmpC single mutant, and this effect was
further enhanced in the DacB-DacC-PbpG-AmpC mutant, indi-
cating that LMM PBPs, particularly DacC, play a role in the in-
trinsic level of-lactam resistance in P. aeruginosa. Our results are
therefore in agreement with recent studies suggesting that E. coli
LMM PBPs, particularly PBP5, play a role in intrinsic -lactam
resistance (26, 27). Purified E. coli PBP5 failed to show significant
-lactamase activity, and therefore it was concluded that the role
of this PBP in intrinsic -resistance might be a consequence of
-lactam trapping. However, interestingly, the recently crystal-
ized P. aeruginosa PBP5 does show certain broad-spectrum (in-
cluding to penicillins, cephalosporins, and carbapenems) -lacta-
mase activity (28). Therefore, the observed effect of PBP5 in P.
aeruginosa intrinsic resistance is expected to result fromboth trap-
ping and hydrolysis of -lactams.
In summary, we have assessed for the first time the effect of P.
aeruginosa LMM PBPs in peptidoglycan structure, defining PBP5
as the major DD-carboxypeptidase, compensated for, if absent, by
PBP4 and PBP7, which additionally show DD-endopeptidase ac-
tivity. Moreover, our results represent a step forward in under-
standing the impact of LMM PBPs in -lactam resistance, appar-
ently driven by the interplay between their effects on AmpC
induction, -lactam trapping, and DD-carboxypeptidase/-lacta-
mase activity.
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